Sellar Masses: An Epidemiological Study

Khaled Al-Dahmani, Syed Mohammad, Fatima Imran, Chris Theriault, Steve Doucette, Deborah Zwicker, Churn-Ern Yip, David B. Clarke, Syed Ali Imran

ABSTRACT: Background: Sellar masses (SM) are mostly benign growths of pituitary or nonpituitary origin that are increasingly encountered in clinical practice. To date, no comprehensive population-based study has reported the epidemiology of SM from North America. Aim: To determine the epidemiology of SM in the province of Nova Scotia, Canada. Methods: Data from all pituitary-related referrals within the province were prospectively collected in interlinked computerized registries starting in November 2005. We conducted a retrospective analysis on all patients with SM seen within the province between November 2005 and December 2013. Results: A total of 1107 patients were identified, of which 1005 were alive and residing within the province. The mean age at presentation was 44.6 ± 18 years, with an overall female preponderance (62%) and a population prevalence rate of 0.1%. Of patients with SM, 837 (83%) had pituitary adenomas and 168 (17%) had nonpituitary lesions. The relative prevalence and standardized incidence ratio, respectively, of various SM were: nonfunctioning adenomas (38.4%; 2.34), prolactinomas (34.3%; 2.22), Rathke’s cyst (6.5%; 0.5), growth hormone–secreting adenomas (6.5%; 0.3), craniopharyngiomas (4.5%; 0.2), adrenocorticotropic hormone–secreting adenomas (3.8%; 0.2), meningiomas (1.9%; 0.2), and others (3.9%; 0.21). At presentation, 526 (52.3%) had masses ≥1 cm, 318 (31.6%) at <1 cm, and 11 (1.1%) had functioning pituitary adenomas without discernible tumor, whereas tumor size data were unavailable in 150 (14.9%) patients. The specific pathologies and their most common presenting features were: nonfunctioning adenoma (incidental, headaches, and vision loss), prolactinomas (galactorrhea, menstrual irregularity, and headache), growth hormone–secreting adenomas (enlarging extremities and sweating), adrenocorticotropic hormone-secreting adenoma (easy bruising, muscle wasting, and weight gain) and nonpituitary lesions (incidentals, headaches, and vision problems). Secondary hormonal deficiencies were common, ranging from 19.6% to 65.7%; secondary hypogonadism, hypothyroidism, and growth hormone deficiencies constituted the majority of these abnormalities. Conclusions: This is the largest North American study to date to assess the epidemiology of SM in a large stable population. Given their significant prevalence in the general population, more studies are needed to evaluate the natural history of these masses and to help allocate appropriate resources for their management.

Keywords: pituitary adenomas, pituitary tumo
doi:10.1017/cjn.2015.301


From the Department of Medicine, Tawam Hospital in affiliation with Johns Hopkins, Al Ain, United Arab Emirates (KAD); Dalhousie University, Halifax, Nova Scotia, Canada (SM, FI); Department of Medicine, Cape Breton Regional Hospital, Sydney, Nova Scotia, Canada (DZ); Division of Neurosurgery, Dalhousie University, Halifax, Nova Scotia, Canada (DBC).

Correspondence to: S. A. Imran, Division of Endocrinology and Metabolism, Dalhousie University, Halifax, NS, Canada B3H 2Y9. Email: simran@dal.ca.
Sellar masses (SM) are mostly benign growths of pituitary or nonpituitary origin that are increasingly encountered in clinical practice. They constitute approximately 14% to 18% of all brain tumors.\textsuperscript{1,2} These tumors may be found incidentally during brain imaging or may present with symptoms of mass effect or profound hormonal abnormalities, resulting in significant morbidity.

Despite their prevalence and clinical importance, relatively few population-based studies, primarily from Europe and Asia, have reported on SM incidence.\textsuperscript{3,4} prevalence.\textsuperscript{5-7} or both.\textsuperscript{8} Data from North America are particularly scarce and are primarily derived from brain tumor registries,\textsuperscript{9} autopsy, or radiological studies.\textsuperscript{10-12} Furthermore, these studies have primarily focused on pituitary adenomas and excluded other sellar and parasellar tumors. To date, no comprehensive population-based study has reported the epidemiology of SM from North America.

We conducted a population-based study to assess the epidemiological trends of clinically manifesting SM in Nova Scotia, Canada. Nova Scotia is a major Atlantic province with a steady population of almost 1 million based on the 2011 census report. Neurosurgery services are only available at Dalhousie University, Halifax, Nova Scotia, which is the major tertiary care referral center, whereas endocrinology services are available either at Dalhousie University or Sydney, Cape Breton, which is a secondary referral center in northern Nova Scotia. All patients with SM are referred to either of the two endocrine centers (Halifax and Sydney) or the neurosurgery center (Halifax). No additional health care in either endocrinology or neurosurgery exists outside these centers in the province. Therefore, this provincial health care setting provides an ideal place to conduct our study, which aims to assess the incidence and the prevalence of SM in a population of almost 1 million.

\section*{Methods and Materials}
\subsection*{Study Design and Methods}

Data from both referral centers (Halifax and Cape Breton), which constitute all pituitary-related referrals within the province, are prospectively collected in a computerized interlinked registry. These include the Halifax Neuropituitary (HNP) and Capital Health Outpatient Clinics databases. A retrospective analysis was carried out on all patients with SM and included any of the following diagnoses: nonfunctioning pituitary adenoma (NFA), prolactinoma, growth hormone (GH)-secreting adenoma, adrenocorticotropic hormone (ACTH)-secreting adenoma, thyroid-stimulating hormone (TSH)-secreting adenoma or any of the nonpituitary tumors including craniohypophyseoma, Rathke’s cleft cyst (RCC), pituitary cyst, meningiomas, or lipomas. The study was approved by the Capital Health Research Ethics Board.

\subsection*{HNP Database}

The HNP clinic was initiated in 2000, whereas the database was first launched in November 2005; it currently contains data on more than 1600 patients. This computerized database prospectively collects demographic, clinical, hormonal, radiological, and surgical data (when applicable) on all patients older than age 16 years with pituitary disorders. All children with SM younger than age 16 within the province are referred to pediatric endocrinology and/or neurosurgery (both solely located in Halifax). Together, these centers receive on average two referrals each year; these patients’ care is subsequently transferred to the HNP clinic once they reach the age of 16. Since November 2005, 13 children were referred for SM, and their data were included in the analysis. All patients at the HNP clinic are followed by a single team comprising an endocrinologist (SAI) and neurosurgeon (DBC) as well as specialized nurses from endocrinology and neurosurgery. Also, this registry collects data on all patients with SM seen by the endocrinology center in Cape Breton.

\subsection*{Capital Health Outpatient Clinics Database}

This database was initiated in June 2009. A small percentage of patients with suspected pituitary disorders are being followed by other adult endocrinologists in the division of endocrinology at Dalhousie University (outside the HNP clinics). Between 2009 and 2013, 126 patients were seen outside the HNP clinic by all other endocrinologists and their charts were reviewed. Of these, only 31 patients had SM (21 had prolactinoma, four nonfunctioning adenoma, two cases of craniopharyngioma, and one case each of ACTH-secreting adenoma, RCC, hypophysitis, and pituitary sarcoidosis).

\subsection*{Diagnostic Strategies for Pituitary-Related Growths}

Pituitary-related growths are generally referred to as pituitary adenomas (PAs). PAs were categorized based on their size into macroadenomas (≥10 mm) or microadenomas (<10 mm) and functional status into either NFA or functioning adenomas (FAs). FAs were further stratified based on the predominant hormonal release pattern as follows. A prolactinoma (PRLoma) was defined as FA associated with detectable PA on imaging, a persistently elevated prolactin level, and presence of symptoms related to high prolactin levels. A subgroup of patients without a detectable MRI lesion but persistently elevated prolactin and absence of secondary causes of hyperprolactinemia such as hypothyroidism, chronic kidney disease, hepatic cirrhosis, and medications known to raise prolactin were defined as MRI-negative PRLoma based on previously published analysis.\textsuperscript{6} GH-secreting adenomas were diagnosed on the basis of typical clinical features, an elevated age, and gender-matched serum insulin-like growth factor-1 and inability to suppress GH following a 75 g oral glucose load. ACTH-secreting adenomas were diagnosed based on clinical and biochemical features of hypercortisolism and evidence of pituitary origin of hypercortisolism based on some or all of the following tests: false normal or elevated ACTH, abnormal dexamethasone suppression test, adequate stimulation with a corticotropin-releasing hormone test, and inferior petrosal sinus sampling with or without a detectable pituitary tumor. TSH-secreting adenoma was diagnosed based on an elevated free T4, inappropriately normal or elevated TSH and presence of pituitary tumor, and a positive tissue diagnosis. NFA was diagnosed when there was no clinical and/or biochemical evidence of hormonal oversecretion and in cases of macroadenoma where serum prolactin was <150 mcg/L (N = 2.1 to 17.7 in males and 2.8 to 29.2 in females). For other sellar and parasellar tumors, the diagnosis was based on typical clinical and radiological features; the latter was judged either by an experienced neurosurgeon or directly obtained from the radiology report. For all patients who underwent surgery, tissue diagnosis was the primary method for making the diagnosis. Secondary hormone insufficiency was defined as follows. Adrenal insufficiency was defined as either basal serum cortisol of
<130 nmol/l, failure of serum cortisol to rise ≥500 nmol/l after an insulin tolerance test, or 250 mcg ACTH stimulation test based on our previously published data. Secondary hypothyroidism diagnosis was based on low free T4 with inappropriate normal or low TSH. Diabetes insipidus was diagnosed based on the presence of polyuria and polydipsia in addition to abnormal water deprivation test. We do not routinely perform dynamic testing for GH deficiency unless coverage for GH therapy is available; therefore, GH deficiency was defined as a low insulin-like growth factor-1.

**Study Population**

Nova Scotia is a major province in Atlantic Canada. The population of the province has remained relatively stable between 2000 and 2013 (932,491 to 945,061). Dalhousie University is the sole tertiary care facility for the province. It is centrally located and caters to patients from southern and central Nova Scotia, whereas Sydney, Cape Breton, which is the second largest health care facility in the province, provides secondary health care for northern Nova Scotia. All pituitary patients within the province are referred to either endocrinology (in Dalhousie University and Sydney) or neurosurgery (Dalhousie University).

**Data Analysis**

Population characteristics were summarized as means with standard deviation for continuous variables and frequencies with percentages for categorical data. Overall prevalence was calculated as the number of patients with diagnoses of SM divided by the Nova Scotia population according to census information provided by Statistics Canada as of December 31, 2013. The World Health Organization 2000 standard population was used to compute standardized incidence rates (SIRs) in all SM as well as specific subtypes. Overall SIR was calculated using average yearly data in the period following the introduction of the HNP database. Incidence and prevalence rates are presented as per 100,000 per year unless otherwise stated. Differences between continuous variables were assessed using the Student t-test. Associations between categorical were analyzed using Fisher’s exact test. All statistical comparisons were two-sided using a significance level of p = 0.05. Analyses were conducted in SAS, version 9.4 (Cary, NC).

**Results**

**Frequency and Distribution of SM**

Between 2005 and 2013, 1107 patients were evaluated for clinically manifesting SM, of which 1005 were alive and residing within the province by December 1, 2013. Their characteristics are summarized in Table 1. Of those who were excluded, 59 had died, whereas 57 were residing outside the province. The mean age on presentation was 44.6 ± 18 years. The age distribution of various SM is shown in Figure 1. There were 624 (62%) females and 381 (38%) males, with an overall preponderance of females across most categories of SM. The rate of diagnosis of SM increased over time, with approximately 234 (23%) being diagnosed before 2000, 235 (23%) between 2000 and 2005, and 536 (53%) diagnosed during the past 8 years (between 2006 and 2013). Of 1005 patients with SM, 838 (83%) had PAs and 167 (17%) had nonpituitary sellar lesions. The most common SMs were NFAs (38.4%), followed closely by PRLoma (34.3%).

Based on the tumor size of all SMs at presentation, 526 (52.3%) presented with masses ≥1 cm and 318 (31.6%) <1 cm, 11 (1.1%) had no discernible tumor, and no tumor size data were available in 150 (14.9%). Of all patients, 665 (66.2%) had no family history of SM in first-degree relatives, 30 (3.0%) had a family history of SM in at least one first-degree relative; data were unavailable in 310 (30.9%) patients.

**Clinical Presentation**

Details concerning features of the clinical presentation are discussed for each SM type. Of all patients, 230 presented as incidental pituitary lesions (prevalence/100,000 = 24.4) and 66 presented with pituitary apoplexy (prevalence/100,000 = 7.0).
Among apoplexy patients, 48 presented with classical features of apoplexy, including severe headaches and visual abnormalities; 15 presented with visual abnormalities; and no information was available for the remaining three patients.

**Pituitary Dysfunction**

Hormonal profiles associated with various SM are summarized in Table 3. Of all SMs, hypophysitis and craniopharyngioma were more likely to be associated with pituitary dysfunction (75% and 71.4%, respectively). Various factors were associated with an increased risk of pituitary hormonal dysfunction in SMs, including: pituitary adenoma (odds ratio = 2.30; 1.47 to 3.59), male gender (2.92; 2.01 to 4.11), and tumors ≥10 mm at presentation, whereas the age at diagnosis and the length of follow-up did not increase the risk of pituitary dysfunction.

**Pituitary Adenomas**

**NFAs**

NFAs were the most frequent SMs, accounting for almost 39% of all SMs and 48% of PAs. The SIR of NFAs was 2.34 and prevalence was 41.34/100,000. There were more women in the NFA group (215/385; 55%) and the mean age of diagnosis was 52.1 ± 16.8 years. The mean age of presentation in women (49.0 ± 17.2 years) was significantly lower than in men (56 ± 15.4 years; p < 0.0001). Of the 385 NFA patients in the HNP database, 269 (70%) presented with macroadenomas, 93 (24%) had microadenomas, and data were unavailable in 23 (6%) patients. Presenting features were clearly identified in 323 (83%) patients and the three most common modes of presentation were: incidental finding in 116 (35%), headache in 108 (32%), and vision loss in 93 (28%). Biochemical data on the complete panel of hypothalamic-pituitary function on presentation were available in 251/385 (65%) patients, of which 107 (43%) had evidence of one or more pituitary axis dysfunction on presentation (see Table 3). The most common deficiency was secondary hypogonadism (34%) followed by secondary hypothyroidism (24%), whereas 11% presented with evidence of dysfunction of three or more axes. Overall, 208 (54%) patients underwent surgical treatment, whereas the rest are being followed clinically.

**Prolactinomas**

PRLomas were the second most prevalent SMs (345/1005), constituting 41% of all PAs, which constituted 34% of all SMs. Prevalence and SIR were 36.67/100,000 and 2.22, respectively. There were more women (242/345; 70%) in the PRLoma group than men (103/345; 30%). The mean age at diagnosis was

![Figure 1: Age Distribution Of Various Sellar Masses.](https://www.cambridge.org/core/i2017/cjn.2015.301)

**Table 2: Incidence rate for the common sellar masses**

<table>
<thead>
<tr>
<th>Year</th>
<th>SIR</th>
<th>NFA</th>
<th>PRLoma</th>
<th>Acromegaly</th>
<th>ACTH adenoma</th>
<th>Rathke’s cyst</th>
<th>Craniopharyngioma</th>
<th>Meningioma</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000</td>
<td>2.57</td>
<td>1.07</td>
<td>0.96</td>
<td>0.08</td>
<td>0.00</td>
<td>0.08</td>
<td>0.37</td>
<td>0.00</td>
</tr>
<tr>
<td>2001</td>
<td>3.86</td>
<td>1.34</td>
<td>1.38</td>
<td>0.29</td>
<td>0.17</td>
<td>0.55</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>2002</td>
<td>3.73</td>
<td>0.95</td>
<td>1.63</td>
<td>0.36</td>
<td>0.26</td>
<td>0.32</td>
<td>0.22</td>
<td>0.00</td>
</tr>
<tr>
<td>2003</td>
<td>3.78</td>
<td>1.05</td>
<td>1.97</td>
<td>0.28</td>
<td>0.07</td>
<td>0.10</td>
<td>0.14</td>
<td>0.00</td>
</tr>
<tr>
<td>2004</td>
<td>3.78</td>
<td>1.37</td>
<td>1.61</td>
<td>0.28</td>
<td>0.08</td>
<td>0.16</td>
<td>0.13</td>
<td>0.08</td>
</tr>
<tr>
<td>2005</td>
<td>4.89</td>
<td>1.91</td>
<td>2.08</td>
<td>0.15</td>
<td>0.24</td>
<td>0.30</td>
<td>0.00</td>
<td>0.08</td>
</tr>
<tr>
<td>2006</td>
<td>6.52</td>
<td>2.45</td>
<td>3.19</td>
<td>0.20</td>
<td>0.07</td>
<td>0.07</td>
<td>0.33</td>
<td>0.08</td>
</tr>
<tr>
<td>2007</td>
<td>4.43</td>
<td>2.00</td>
<td>1.29</td>
<td>0.37</td>
<td>0.14</td>
<td>0.14</td>
<td>0.29</td>
<td>0.11</td>
</tr>
<tr>
<td>2008</td>
<td>5.46</td>
<td>2.17</td>
<td>1.71</td>
<td>0.33</td>
<td>0.25</td>
<td>0.55</td>
<td>0.11</td>
<td>0.08</td>
</tr>
<tr>
<td>2009</td>
<td>7.34</td>
<td>2.95</td>
<td>2.12</td>
<td>0.21</td>
<td>0.27</td>
<td>0.49</td>
<td>0.26</td>
<td>0.28</td>
</tr>
<tr>
<td>2010</td>
<td>6.62</td>
<td>2.08</td>
<td>2.86</td>
<td>0.13</td>
<td>0.21</td>
<td>0.60</td>
<td>0.14</td>
<td>0.12</td>
</tr>
<tr>
<td>2011</td>
<td>6.64</td>
<td>2.13</td>
<td>2.59</td>
<td>0.31</td>
<td>0.06</td>
<td>1.07</td>
<td>0.12</td>
<td>0.05</td>
</tr>
<tr>
<td>2012</td>
<td>5.91</td>
<td>2.55</td>
<td>2.20</td>
<td>0.35</td>
<td>0.06</td>
<td>0.32</td>
<td>0.18</td>
<td>0.12</td>
</tr>
<tr>
<td>2013</td>
<td>6.25</td>
<td>2.35</td>
<td>1.83</td>
<td>0.38</td>
<td>0.29</td>
<td>0.72</td>
<td>0.06</td>
<td>0.19</td>
</tr>
</tbody>
</table>
37.0 ± 14.9 years, with 55.2% of all PRLomas diagnosed between the ages of 20 and 40 years. Data on tumor size at presentation were available in 281/345 (81%) of patients, of which 163/281 (58.0%) presented with microadenomas, 110/280 (39.1%) had macroadenomas, and 8/281 (3%) had no discernible adenoma on MRI. Gender difference was noted in tumor size in that 63/110 (57.3%) of males presented with macroadenomas compared with only 31/163 (19%) of females (p < 0.0001). The most common presenting features in women were galactorrhea (41%), amenorrhea (39%), and menstrual irregularity (17%), whereas in men these were decreased libido (37%), headache (28%), and incidental findings (21%). Ninety-three percent of PRLoma patients were treated with medical therapy, whereas 7% had undergone surgery as the primary mode of treatment. Complete pituitary profile at presentation was available in 51% of PRLoma patients, of which almost 66% had evidence of at least one hormonal axis deficiency at diagnosis with secondary hypogonadism being the most common deficiency in almost 54% patients (see Table 3).

### GH-Secreting Adenomas

Following PRLoma, GH-secreting adenoma patients constituted the second most common functioning adenomas, constituting 7.8% of PA and 6.5% of all SM, with a SIR of 0.3 and prevalence of 6.90/100,000. The mean age at diagnosis was 46.8 ± 15.0 years. Females constituted 53% of GH-secreting adenoma patients. At presentation, 44 (68%) had macroadenoma, nine (14%) had microadenoma, one (0.01%) had no discernible tumor, and no data were available in 10 (16%) patients. The most common presenting features included: enlarging shoe size (45%), increasing ring size (26%), and sweating (26%). Complete hormonal profile at presentation was available in 37 (58%) patients, of which 15 (41%) had evidence of pituitary dysfunction (Table 3), with secondary hypogonadism being the most common hormonal deficiency (32%), followed by secondary hypothyroidism (22%); one patient had three or more hormonal deficiencies. The primary mode of therapy in patients with GH-secreting adenomas was surgery in 60 (94%), whereas four (6%) patients were initiated on medical therapy as the primary treatment.

### ACTH-Secreting Adenomas

There were 38 patients with ACTH-secreting adenomas, which constituted 4.5% of all PAs. The overall prevalence was 4.03/100,000 and SIR was 0.2. Women by far constituted the majority of the group (30/38; 79%). The mean age at diagnosis was 43.5 ± 16.5 years. Tumor size data at presentation showed that 14 (38%) had macroadenoma, eight (21%) had microadenoma, two (5%) had no discernible adenoma, and no data were available for 13 (35%) patients. The most common clinical features at diagnosis were easy bruising (54.2%), rapid weight gain (45.8%), and proximal muscle weakness (37.5%). A complete panel of pituitary function was available in 19 (50%) patients, of which seven (37%) presented with one or more hormonal insufficiencies—the most common being secondary hypogonadism in five (26%), secondary hypothyroidism in four (21%), and one patient had three or more insufficiencies. Pituitary surgery was the primary mode of therapy for all ACTH-secreting adenoma patients.

### Nonpituitary SMs

**RCC**

RCC was the most common nonpituitary SM (65/167), constituting 39% of all nonpituitary SMs and 6.5% of all SMs with a SIR of 0.5 and prevalence of 6.90/100,000. Similar to most other SMs, there were more females 39 (61%), and the mean age at diagnosis was 46.0 ± 15.3 years. The most common modes of presentation were incidental finding (71%), headache (28%), and vision abnormalities (12%). One-third (32%) of patients with RCC required surgery, whereas others are being followed conservatively. Tumor size at presentation was available in 58 (89%) patients, of which 34 (59%) were ≥1 cm. Hormonal values on presentation were available in 46 (72%), of which nine (20%) had evidence of pituitary dysfunction: secondary hypothyroidism (15%), secondary hypogonadism (13%), and secondary hypoadrenalism (11%). Three or more hormonal axes deficiencies were seen in four patients (9%).

**Cranioopharyngioma**

Forty-five patients (4.5% of all SMs) had craniopharyngiomas with a SIR of 0.2 and prevalence of 4.78/100,000. The mean age of presentation was 31.6 ± 22.1 years, whereas eight patients presented before the age of 10 years. There were more men (25/45; 55%) in this group; of the 27 patients whose tumor size on presentation was known, 22 (81%) presented with tumor ≥10 mm. The most common modes of presentation were headaches (44%), vision abnormalities (41%), and incidental finding (33%)—and almost half (53%) required surgery as primary therapy. Data on hormonal function at presentation were available in

---

**Table 3: Hormonal profile of the common sellar masses**

<table>
<thead>
<tr>
<th>Type of SM</th>
<th>Hormonal deficiencies</th>
<th>GH deficiency</th>
<th>Hypogonadism</th>
<th>Hypothyroidism</th>
<th>Adrenal Insufficiency</th>
<th>Diabetes Insipidus</th>
<th>3 or more</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonfunctioning adenoma</td>
<td>107/251 (42.6%)</td>
<td>35 (13.9%)</td>
<td>86 (34.3%)</td>
<td>60 (23.5%)</td>
<td>27 (10.8%)</td>
<td>3 (1.2%)</td>
<td>28 (11.2%)</td>
</tr>
<tr>
<td>Prolactinoma</td>
<td>115/175 (65.7%)</td>
<td>19 (10.9%)</td>
<td>94 (53.7%)</td>
<td>29 (16.6%)</td>
<td>5 (2.9%)</td>
<td>0 (0%)</td>
<td>11 (6.3%)</td>
</tr>
<tr>
<td>GH adenoma</td>
<td>15/37 (40.5%)</td>
<td>0 (0%)</td>
<td>12 (32.4%)</td>
<td>8 (21.6%)</td>
<td>1 (2.7%)</td>
<td>0 (0%)</td>
<td>1 (2.7%)</td>
</tr>
<tr>
<td>ACTH adenoma</td>
<td>7/19 (36.8%)</td>
<td>0 (0%)</td>
<td>5 (26.3%)</td>
<td>4 (21.1%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (5.3%)</td>
</tr>
<tr>
<td>RCC</td>
<td>9/46 (19.6%)</td>
<td>1 (2.2%)</td>
<td>6 (13%)</td>
<td>7 (15.2%)</td>
<td>5 (10.9%)</td>
<td>0 (0%)</td>
<td>4 (8.7%)</td>
</tr>
<tr>
<td>Craniopharyngioma</td>
<td>15/21 (71.4%)</td>
<td>7 (33.3%)</td>
<td>10 (47.6%)</td>
<td>9 (42.9%)</td>
<td>5 (23.8%)</td>
<td>2 (9.5%)</td>
<td>6 (28.6%)</td>
</tr>
<tr>
<td>Meningioma</td>
<td>1/10 (10%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (10.0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>
21 (47%) patients (see Table 3), of whom 15 (71%) had evidence of pituitary hormonal dysfunction, with six (29%) presenting with multiple hormonal deficiencies.

**Meningiomas**

Nineteen patients had sellar or parasellar meningiomas with prevalence of 2.01/100,000 and a SIR of 0.21. At presentation, 18 had tumors ≥1 cm, whereas 1 was <1 cm. The most common modes of presentation were vision loss (60%), incidental finding (33%), and headache (13.3%). Hormonal dysfunction data for meningioma are summarized in Table 3.

**“Other” Sellar Lesions**

Thirty-nine patients were categorized as having “other” lesions, with a total prevalence of 4.14/1000. These included: cystic pituitary lesions (16), hypophysitis (five), arachnoid cyst (five), histiocytosis (four), nonspecific hypothalamic lesions (three), atypical epithelial neoplasm (two), and one each of germinoma, TSH-secreting adenoma, plasmacytoma, and osteolipoma. There was no case of gonadotropin-secreting adenoma in our series. The overall SIR of these lesions was 0.13. There were no cases of pituitary carcinoma in our study. Hormonal information in four of five patients with hypophysitis was available, of which three (75%) had evidence of dysfunction. Two (50%) had GH deficiency, one (25%) had secondary hypogonadism, two (50%) had secondary hypothyroidism, two (50%) had secondary adrenal insufficiency, and two (50%) had diabetes insipidus.

**Discussion**

To our knowledge, this is the largest North American population-based study to evaluate the epidemiology of clinically manifesting pituitary and nonpituitary SM describing their incidence over a 7-year period. In this study, we report an overall prevalence of 0.1% for all SMs. PAs constituted the vast majority of SM in our study, with a prevalence and SIR of 82.2 and 5.0 per 100,000, respectively. Our data are in agreement with the reported prevalence rates from Belgium, the United Kingdom, and Malta, which ranged between 75.7 and 94/100,000.5,6,8 Concurrency with these reports suggests that the prevalence of PAs has been stable over the past decade and is similar across different geographic areas. Similarly, the incidence of PAs, although slightly higher in our study (5.0), is comparable with the previously reported incidence of 3.9 to 4.27 from other centers.3,8 However, the relative distribution of various subtypes of PAs was somewhat different in that, unlike other studies that reported PRLomas being the most common PA,2-6 our data showed that the most common subtype was NFA (38.7%) followed by PRLoma (34.3%). The prevalence and incidence rates of GH-secreting adenomas, ACTH-secreting adenomas, and TSH-secreting adenomas were comparable to previous data. The overall SIR of incidental pituitary lesions in our study was 1.62, which is comparable with other studies that have reported the incidence of 0.59 to 1.6/100,000.3,6

Our study is unique in that we studied the epidemiology of all SMs. Of the nonpituitary SMs, RCC was the most common entity (6.5% of all SMs) and where 71% of all RCCs were detected incidentally and most of them were >1 cm, would suggest that the actual prevalence of RCC may be even higher. A similar trend has been reported in other studies where RCC constitutes 18.6 to 27.5% of incidental SMs,10-12 suggesting a much higher prevalence of RCC than what we have reported. Similar to RCC, craniopharyngiomas are benign, slow-growing SMs with an unknown prevalence but an incidence of 0.17 to 0.19/10,000 based on the most recent studies.14,15 The prevalence of craniopharyngioma in our study was 4.8/100,000 with a SIR of 0.2. To our knowledge, this is the first study to evaluate the incidence of craniopharyngioma in a large population. Although intracranial meningiomas represent about one-third of all primary brain tumors,14 information regarding sellar/parasellar meningiomas is not widely available. This may at least in part be due to referral patterns and institutional practice in which meningiomas of the sellar/parasellar region may be seen and managed without referral to a pituitary service. In our experience, for example, only with the development of endoscopic transsphenoidal surgery (beginning in 2004) did we start to see patients referred for management of meningiomas. Therefore, one must be cautious when interpreting these data. Our data show that the sellar/parasellar meningiomas referred to us were larger lesions and frequently associated with significant pituitary hormonal dysfunction. Our findings emphasize the need for comprehensive hormonal assessment at the time of diagnosis of sellar/parasellar meningiomas.

Although SM can affect patients of any age group, our study showed distinct association between certain age ranges and SM. A vast majority of patients presenting before the age of 10 had craniopharyngioma (64%), whereas 51% within the age range of 10 to 39 years had PRLomas and 51% older than age 40 years had NFAs. This finding is expected given that craniopharyngiomas are derived from embryological remnants of the Rathke’s pouch and, therefore, any related abnormality would likely present early in life. This is concordant with previously published data showing the peak incidence of craniopharyngioma in children between the ages of 5 and 9 years.12 Similarly, clustering of PRLomas within the reproductive age group of 20 to 40 years in our study is also in agreement with previous work.8

Hypopituitarism can occur in patients with SM depending on factors such as the size, type, and location of the tumor. Previously published studies have not consistently documented hormonal profiles of the patients presenting with SM and, to our knowledge, this study is the only one that has systematically assessed pituitary hormonal function in relation to various types of SMs. Our data showed a high risk of hypopituitarism, varying between different subtypes from 36.8% to 75%, with the highest being in patients with hypophysitis or craniopharyngiomas. Almost 43% of our NFA patients had some degree of pituitary insufficiency. Previous studies have reported partial pituitary dysfunction rate of 61% in a select population of large NFA undergoing surgery16 and approximately 80% in large PRLomas.17

Diabetes insipidus is a rare complication of SM with an uncertain prevalence. In one study of 444 patients with pituitary tumors, nine (2%)—of which six either had surgery or apoplexy—had diabetes insipidus.18 Our study showed that only 1.2% of NFA patients presented with diabetes insipidus, whereas the highest risk of diabetes insipidus occurred in patients with hypophysitis (50%) and craniopharyngiomas (9.5%), findings that are consistent with previous studies reporting a high risk of diabetes insipidus in hypophysitis (52%) and in childhood craniopharyngioma (8% to 35%).19,20

Our study has several strengths. It is the largest North American study based on a stable provincial population. Furthermore, we have
obtained comprehensive data from all centers, which has been prospectively collected during 8 years. A stable SIR over time further strengthens the comprehensiveness of our dataset. Additionally, we have reported the epidemiology on all SMs, unlike many previous studies that primarily focused on PAs alone. However, there are limitations to our study. Not all data in our study were prospectively collected; data collected before 2006 were obtained retrospectively through chart review, and some elements of the data were not consistently available. Additionally, the rates of GH deficiency in our cohort may not be accurate because we do not consistently perform dynamic testing for GH deficiency. Unlike other hormone replacement, the cost of GH therapy is not routinely covered by provincial health insurance; therefore, we reserve dynamic testing only for select patients who are granted provincial coverage or who have private coverage for GH therapy.

CONCLUSIONS

The epidemiology of SMs in our study, the largest series from North America, shows a prevalence of 0.1% and a stable SIR of 6.15. Our data also show distinct age and gender distributions of these lesions and a high risk of associated pituitary dysfunction. More studies are needed to evaluate SMs’ natural history and help allocate appropriate resources to their management.

DISCLOSURES

None of the authors has anything to disclose.

REFERENCES